Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD8 MicroBeads, human

RRID:AB_2889920
Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-045-201, RRID:AB_2889920

Antibody Information

URL: http://antibodyregistry.org/AB_2889920

Proper Citation: Miltenyi Biotec Cat# 130-045-201, RRID:AB_2889920

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: positive selection or depletion of human cytotoxic CD8+ T cells

Antibody Name: CD8 MicroBeads, human

Description: This monoclonal targets CD8

Target Organism: human

Antibody ID: AB_2889920

Vendor: Miltenyi Biotec

Catalog Number: 130-045-201

Record Creation Time: 20250819T215222+0000

Record Last Update: 20250820T002203+0000

Ratings and Alerts

No rating or validation information has been found for CD8 MicroBeads, human.

No alerts have been found for CD8 MicroBeads, human.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Geng H, et al. (2026) Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. Developmental cell, 61(5), 995.

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1557.

Bernasconi-Bisio F, et al. (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. Molecular therapy. Oncology, 33(1), 200949.

Chen J, et al. (2025) CD146+ CAFs mediate immunosuppression in gastric cancer via COL4A1: potential therapeutic targets. Journal for immunotherapy of cancer, 13(12).

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. bioRxiv : the preprint server for biology.

Libri AB, et al. (2025) Senataxin promotes recombination fidelity during antigen receptor gene diversification. Science signaling, 18(908), eadv8801.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence. Cell reports. Medicine, 5(5), 101550.

Hirsch T, et al. (2024) IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression. Cell reports, 43(7), 114401.

Moskovljevic M, et al. (2024) Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapy. Immunity, 57(12), 2928.

Brown AC, et al. (2023) Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis. Cell genomics, 3(6), 100306.

Barbieri L, et al. (2023) Lactate exposure shapes the metabolic and transcriptomic profile of CD8+ T cells. Frontiers in immunology, 14, 1101433.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(12), 2250.

Canale FP, et al. (2023) Proteomics of immune cells from liver tumors reveals immunotherapy targets. Cell genomics, 3(6), 100331.

Bonté PE, et al. (2022) Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. Cell reports, 39(10), 110916.